ThinkSono is FDA-cleared. What that actually took.

ThinkSono has received FDA 510(k) clearance for ThinkSono Guidance, the first AI-powered ultrasound guidance software cleared for evaluating suspected deep vein thrombosis. Congratulations to Fouad Al Noor, Sven Mischkewitz, and the entire team.

We backed Fouad and Sven at pre-seed, when ThinkSono was two founders out of Entrepreneur First and one conviction: capturing a blood clot scan shouldn't require a specialist. That was a decade ago.

What was actually cleared

ThinkSono Guidance doesn't read ultrasound images — it guides the person holding the probe. The app connects to a compatible handheld scanner, highlights vascular structures in real time, and prompts the operator to record when the view is right. The clips then go to a remote qualified clinician who grades image quality and assesses vein compressibility.

Every clinical decision stays with that clinician. The software removes the need for a sonographer to be physically present at capture — a narrower claim than "AI detects blood clots," and a much better business.

Why DVT

Venous thromboembolism affects up to 900,000 people in the US annually and contributes to an estimated 60,000–100,000 deaths, per the CDC. A DVT is cheap to treat and dangerous to miss. Standard compression ultrasound depends on trained sonographers whose availability thins overnight, on weekends, and in rural areas. This isn't a technology gap — it's a distribution gap in who is allowed and able to hold the probe.

The evidence

• Operators performed exams after 60–90 minutes of standardized training

• Median scan time: 5:24, median remote review: 2:13

• Pivotal US study: 594 patients across five sites

• Total: 1,691 patients across 24 US and international sites, including 157 confirmed DVTs

• Pooled sensitivity 92.9%, prioritization specificity 97.1%, adequate image quality 87.1%

• Consistent performance across age, sex, BMI, and race/ethnicity subgroups

• Breakthrough Device Designation granted February 2026

Prospective, double-blinded, multicenter — every exam measured against a reference-standard specialist scan.

What this doesn't mean

A clearance is permission to sell, not proof anyone will buy. ThinkSono now faces reimbursement pathways, hospital procurement, clinical champions, and the work of changing a 30-year-old pathway. Anyone treating FDA clearance as the finish line hasn't sold into a health system.

Thanks

Congratulations again to Fouad Al Noor, Sven Mischkewitz, Prof. Michael Blaivas, Dr. Dignesh Shah and everyone at ThinkSono who spent the last decade on the parts nobody posts about.

cc: Dr. Jens Schmidt-Sceery, Frank Pawlitschek, Michael Mansfeld